ASCO 2020：11项华南地区研究入选口头报告，17项Poster报告

受亚洲地区新冠疫情影响，原定于5月末29日~6月末2日在芝加哥参加的美国诊断学可能会（ASCO）年可能会上周将首次以线上形式筹办，这是目前最大规模的线上盛可能会。今天，决议的参考资料题目公布，共103个sessions，中的国分别为11项科学研究入围口头报告，17项入围Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或卡洛替尼加卡培他滨用于HER2+移往性乳腺前列腺癌（PHOEBE）：一项III期随机实验。

演奏会：移往性乳腺前列腺癌

编者：中的国医学科学院的医院徐兵河研究员、马飞研究员，浙江大学所的医院胡夕春研究员等

参考资料号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性乳腺前列腺癌标准疗法后卡培他滨维持节拍化学疗法的III期实验（SYSUCC-001）。

演奏会：乳腺前列腺癌—发散/周围/除此以外疗法

编者：中的山大学传染病中的心王时树森研究员等

参考资料号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

透过移往性脑的表型特征来计算十二指肠中的循环DNA测定的可能性: 新工具对抗杨家劲敌

演奏会：新工具解决杨家问题

编者：陈美芹 陈德兰等

参考资料号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为早期肝消化道内前列腺癌的一线疗法：一项停止使用标识、随机、多中的心II/III期实验。

演奏会：十二指肠肠道前列腺癌—十二指肠静脉、胰腺和实无

编者：浙江大学华西的医院毕锋研究员、中的国人民解放军淮海的医院秦叔逵研究员等

参考资料号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国早期肝前列腺癌病征阿帕替尼三线疗法：一项随机、双盲对照、双盲III期科学研究

演奏会：十二指肠肠道前列腺癌—十二指肠静脉、胰腺和实无

编者：中的国人民解放军淮海的医院秦叔逵研究员、浙江大学华西的医院陈秋研究员等

参考资料号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期膀胱癌卵巢前列腺癌二次消化道内减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

专刊：外科前列腺胃癌

编者：浙江大学附属中的山的医院臧荣余研究员等

参考资料：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈前列腺癌根治性内膜切除术后除此以外疗法中的的序贯放化学疗法对比单独放疗或同步放化学疗法（STARS科学研究）：一项随机、对照、停止使用标识的III期实验。

决议：外科前列腺胃癌

编者：中的山大学传染病中的心黄鹤研究员、刘继红研究员等

参考资料号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：除此以外吉非替尼对比化学疗法用于可切除的EGFR凋亡的N1-N2期NSCLC-随机III期抗病毒的再度各个方面求生研究。

专刊：肺前列腺癌—非小消化道内发散-周围/小消化道内/其他臀部

编者：广东省人民的医院吴一龙研究员等

参考资料号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR凋亡辄移往非小消化道内肺前列腺癌病征一线色氨酸激酶抑制剂共同或不共同更进一步前线发散放疗：III期停止使用标识诊断随机实验（SINDAS）的中的期结果（NCT02893332）。

专刊：肺前列腺癌-非小消化道内移往

编者：四川省人民的医院曾铭研究员等

参考资料：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对一般而言死亡-1（PD-1）的人源化IgG4单克隆抗体共同阿昔替尼用于移往性黏膜脑疣病征的Ib期科学研究的总求生期和生物标志物研究。

专刊：脑疣/皮肤前列腺癌

编者：南开大学的医院郭军、盛锡楠研究员等

参考资料：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全性和结果：国际标准化组织CAR-T消化道内首次消化道实验疗法复发/难治性T消化道内急性淋巴消化道内乳癌（r/r T-ALL）的安全性和。决议：开发中的的疗法技术-免疫疗法。编者：王时好在等参考资料：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在早期静脉点状消化道内前列腺癌病征中的的应用：一项随机的停止使用标识II期实验（ORIENT-2）。决议：十二指肠肠道前列腺癌-十二指肠静脉前列腺癌、胰腺前列腺癌和实无道前列腺癌编者：徐建明研究员等参考资料：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T消化道内对髓母消化道内疣的根除性疗法决议：中的枢神经系统编者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、郑旭东参考资料：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复缺陷病征中的的应用决议：开发中的的疗法学-免疫疗法编者：沈琳研究员等参考资料：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗法复发/难治性ACUTE淋巴消化道内乳癌/霍奇金的尚未有消化道抗病毒决议: 开发性疗法学-免疫疗法编者简介：张明志，杨林等参考资料：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 科克替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）共同应用早期实体疣病征的Ib期科学研究决议：发展性疗法学--分子结构类似物药物和生物学编者：龚继芳，沈琳研究员等参考资料：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin共同紫杉醇和nedaplatin疗法膀胱癌或移往性静脉点状消化道内前列腺癌（ESCC）病征的II期科学研究。决议：十二指肠肠道前列腺癌-十二指肠静脉、胰腺和实无道前列腺癌的科学研究编者：王时志强，陈玉红，王时德申，王时凤华，任超，谭琼 王时志强、陈玉红、王时德深、王时凤华、任超、谭琼参考资料：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.决议：十二指肠肠道前列腺癌-十二指肠静脉前列腺癌、胰腺前列腺癌和实无管前列腺癌的三线疗法编者：宋艳等参考资料：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种分泌物外体外侧RNA分类器用于初始前列腺时测定高等级前列腺癌的分泌物外体外侧RNA分类器：一项多中的心的回顾性科学研究决议：外科生殖系统前列腺胃癌--前列腺癌、睾丸前列腺癌和前列腺癌编者简介：Liaoyuan Li等参考资料：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散早期宫颈前列腺癌并发化学疗法后的除此以外化学疗法决议: 外科前列腺胃癌编者简介： 陈珉珉等参考资料：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗法甲状腺髓性前列腺癌的相关性：基于ALTER01031实验的研究。可能会广府：皮脂腺编者：天津市的医院高明研究员参考资料：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小不一和年龄对安洛替尼疗法后病征结局的影响: ALTER01031的亚组研究决议：皮脂腺编者：天津市的医院高明研究员参考资料：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA研究计算I-IIIA期非小消化道内肺前列腺癌（NSCLC）病征术后复发: GASTO1035和GASTO1018的结果决议：肺前列腺癌-非小消化道内发散-周围性/小消化道内/小消化道内/其他胸科前列腺胃癌编者：Si-Yu Wang等参考资料：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小消化道内肺前列腺癌（NSCLC）中的EGFR色氨酸激酶抑制剂的新型耐药机制决议:肺前列腺癌-非小消化道内移往性肺前列腺癌编者简介：郑昕，金恰巧，满宇，欧春花，华宝，薛武，杨少，范敏 郑昕、金恰巧、满宇、欧春花、华宝、薛武、杨绍、范敏参考资料：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验中的早期脑疣总求生的替代往南决议：脑疣/皮肤前列腺癌编者：聂润聪，袁书强，陈元芳，陈英波，周志伟 聂润聪、袁书强、陈元芳、陈英波、周志伟参考资料：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗法复发或移往性病症恶性骨病征的II期科学研究决议： 肉疣编者：唐丽娜，牛晓辉，陈赓，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王时振、蔡启庆、涂崇奇、范正福、杨瑶参考资料：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在早期肉疣病征多线疗法中的的安全性和。决议：肉疣编者：姚伟涛，王时家强，张鹏，王时欣，杜新辉，田志浩，牛晓颖 姚伟涛、王时家强、张鹏、王时鑫、杜鑫辉、田志超、牛晓英参考资料：11526标语：414